CalciMedica announces publication in the American Journal of Nephrology discussing design and rationale of Phase 2 KOURAGE trial of Auxora™ in AKI with respiratory failure

/in

CalciMedica announces publication in the American Journal of Nephrology discussing design and rationale of Phase 2 KOURAGE trial of Auxora™ in AKI with respiratory failure LA JOLLA, Calif., June 25, 2025 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and […]

Read more

CalciMedica Announces Upcoming Presentations and Events in September

/in

LA JOLLA, Calif., Sept. 6, 2023 /Link here/ — CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer, will participate in a presentation at the H.C. Wainwright 25th […]

Read more

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

/in

LA JOLLA, Calif., Aug. 31, 2023 /PRNewswire/ Link here — CalciMedica Inc. (“CalciMedica”) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a virtual clinical experts event on Thursday, September 21, 2023, from 10:30 […]

Read more

CalciMedica Expands Executive Team with New Appointments

/in

Raven Jaeger, M.S. named Chief Regulatory Officer and Andrew Cunningham, M.D., MRCPI, named Senior Vice President, Clinical Development LA JOLLA, Calif., May 23, 2023 (GLOBE NEWSWIRE) — Link here: CalciMedica Inc. (“CalciMedica”) (OTCQB: CALC), a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need, today announced the appointments of […]

Read more

CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement

/in

LA JOLLA, Calif., March 20, 2023 (GLOBE NEWSWIRE): News Link – CalciMedica common stock to commence trading on Nasdaq Global Market on March 21, 2023 under ticker symbol “CALC” – Cash and cash equivalents of approximately $34 million as of merger close expected to support operations into the second half of 2024 – Phase 2b results in acute pancreatitis for lead […]

Read more

Graybug and CalciMedica Enter into Definitive Merger Agreement

/in

November 21, 2022 18:52 ET | Source: Graybug Vision, Inc.; CalciMedica Inc. Link here  Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into […]

Read more

CalciMedica Announces Publication of Preclinical Data in EMBO Molecular Medicine Supporting the Development of CRAC Channel Inhibitors for Inflammatory Bowel Disease (IBD)

/in

  Study provides further validation of the potentially broad utility for CRAC channel inhibitors in inflammatory diseases Data show that inhibiting store-operated Ca2+ entry (SOCE) with a selective CRAC channel inhibitor reduced IBD severity in murine models LA JOLLA, Calif., Aug. 9, 2022 /PRNewswire/ — CalciMedica Inc. (“CalciMedica” or the “Company), the CRAC (calcium release-activated calcium) channel company, today announced […]

Read more

CalciMedica Announces Publication of Results from CARDEA COVID-19 Study in Critical Care

/in ,

Link to full article April 14, 2022 – Results further support therapeutic potential of Auxora in respiratory diseases and other inflammatory diseases – LA JOLLA, Calif., April 14, 2022 – CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the publication of results from the Company’s CARDEA clinical trial, a Phase […]

Read more

CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology

/in ,

Link to full article March 10, 2022 Study Supports Development of CRAC Channel Inhibitors for Acute Pancreatitis Study indicates that Orai1 inhibition prevents impaired ductal cell function in acute pancreatitis (AP) Data describes underlying biological mechanisms that may explain key result in a Phase 2a trial of AuxoraTM in patients with AP with systemic inflammatory response […]

Read more

CalciMedica Initiates CARDEA-Plus: A Clinical Trial of Auxora™ in Patients with Critical COVID-19 Pneumonia

/in ,

Link to full article January 20, 2022 CARDEA-Plus is designed to evaluate dosing, safety and efficacy of Auxora in combination with both tocilizumab and corticosteroids CalciMedica Inc. (CalciMedica or the Company), the CRAC (calcium release-activated calcium) channel company, today announced the initiation of CARDEA-Plus, a Phase 2b clinical trial being conducted in the United States […]

Read more